The FDA announced it is analyzing data to determine whether there are any long-term risks conferred by paclitaxel-coated products used in patients with peripheral artery disease.
In a letter to health care providers, the agency also told clinicians to continue monitoring patients treated with paclitaxel-coated balloons and paclitaxel-eluting stents in accordance with the standard of care, and to discuss with patients with PAD the risks and benefits of all available treatment options.
Supported by independent medical education grants from the Amyloidosis Research Consortium and Pfizer
American Heart Association Scientific Sessions
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.